John Shiver

Title: **John Shiver: Innovator in Meningococcal B Vaccine Development**

Introduction

John Shiver is a prominent inventor based in Cambridge, MA, recognized for his significant contributions to the field of immunology. With a focus on developing effective vaccines, he has achieved notable accomplishments in the realm of public health.

Latest Patents

John Shiver holds a patent for the Meningococcal B recombinant vaccine. This innovative immunogenic composition comprises a combination of meningococcal antigens, including at least one factor H binding protein (fHBP) A protein, at least one fHBP B protein, at least one adhesin A (NadA) protein, and at least one detergent-extracted Outer Membrane Vesicle (dOMV). The unique combination of these antigens provides broad coverage against various serogroup B bacteria strains. Furthermore, this patent outlines the use of the immunogenic composition in methods aimed at eliciting a robust immune response.

Career Highlights

John is currently affiliated with Sanofi Pasteur Inc., where he continues to work on groundbreaking vaccine research and development. His dedication to improving public health through innovative solutions has made a considerable impact in the field of immunology.

Collaborations

Throughout his career, John has collaborated with notable peers, including Nadège Arnaud-Barbe and Vinod Balhara. These collaborations have enhanced the research and development processes, leading to advancements in vaccine technology.

Conclusion

John Shiver's work exemplifies the spirit of innovation in the healthcare sector. His patented Meningococcal B recombinant vaccine is a testament to his commitment to public health and his expertise in vaccine development. As he continues to push the boundaries of scientific discovery, his contributions will undoubtedly play a crucial role in combating infectious diseases.